Influenza
Conditions
Keywords
Influenza, Pandemic Influenza Vaccine (GSK1562902A)
Brief summary
The present study is designed to evaluate in children (aged between 3 and 9 years) the immunogenicity and safety of different antigen doses of the candidate vaccine (GSK1562902A) administered following a two-administration schedule (21 days apart). Subjects in the control group will receive Fluarix. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Detailed description
This 107066 study is a participating study to the broader NCT00502593 study, which included 2 other studies, the 108498 and 108500 studies. The NCT00502593 study had a staggered design (subjects from each group being enrolled sequentially into 2 age strata, '6-9 years' 1st, and '3-5 years' next) and was run in 3 phases, phases A (Study 107066), B (Study 108498) and C (Study 108500). In each phase, the decision to vaccinate subjects aged 3-5 years and to administer a 2nd injection to subjects aged 6-9 years was made based on safety data collected on Days 0-6 after the 1st injection for the subjects aged 6-9 years. Decision to start Phase B was made on complete safety data including those collected on Day 28 of Phase A (7 days after the 2nd injection) for each age group. A similar approach was to be used to start Phase C. As safety data in Phase A did not raise any safety concerns, Phases B and C were run in parallel.
Interventions
BIOLOGICALPandemic Influenza Vaccine (GSK1562902A)
2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
BIOLOGICALFluarix™
2 doses, intramuscular injection on Days 0 and 21.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 9 Years
Healthy volunteers
Yes
Inclusion criteria
* Children who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. * Children aged between and including 3 and 9 years of age at the time of first vaccination. * Written informed consent obtained from the parent(s) or guardian of the subject. * Healthy children as established by medical history and clinical examination before entering the study. * Subjects who are likely to reside in the vicinity of the study center for the duration of the study.
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the investigational vaccine within 30 days prior to the enrolment in this study, or planned use during the study period. * Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination, with the exception of routine childhood inoculations which cannot be delayed, but which must not be administered on the same day as the investigational vaccine candidate. * Administration of the interpandemic influenza vaccine 21 days prior to Day 0 or up to Day 51. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the enrolment in this study. * Any chronic drug therapy to be continued during the study period, with the exception of inhalative treatment for seasonal allergies or asthma. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination. * History of hypersensitivity to vaccines. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccines used in this study. * History of any neurological disorders or seizures. * Acute disease at the time of enrolment. * Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study or planned during the study. * Any condition which, in the opinion of the investigator, renders the subject unfit for participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | At Days 0, 21 and 42 and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents LDH results, for subjects participating to Phase C of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents ALT results, for subjects participating to Phase C of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CPK results, for subjects participating to Phase B of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results, for subjects participating to Phase C of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CPK results, for subjects participating to Phase C of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | At Days 0, 21 and 42 and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CREA results, for subjects participating to Phase C of the study. |
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | At Day 0 | Titers of serum HI antibodies are presented as geometric mean titers (GMTs). The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10. |
| Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | At Day 21 | A seroconverted subject was a subject with a pre-vaccination serum haemagglutination-inhibition (HI) antibody titer below (\<) 1:10 and a post-vaccination HI antibody titer above than or equal to (≥)1:40 or a pre-vaccination HI antibody titer ≥ 1:10 and at least four-fold increase in post-vaccination HI antibody titer. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). |
| Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | At Day 21 | The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). |
| Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | At Day 0 | A seroprotected subject was defined as a vaccinated subject with a haemagglutination-inhibition (HI) antibody titer above or equal to the seroprotection threshold of 1:40. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO). |
| Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | During the 7 day follow-up period after each vaccination | Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal activities. Grade 3 ecchymosis/induration/redness/swelling = ecchymosis/induration/redness/swelling larger than (\>) 100 millimeters (mm). All solicited local symptoms were considered to be related to study vaccination. This outcome presents results from subjects participating in Phase A of the study. |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During the 7-day (Days 0-6) follow-up period after any vaccination | Assessed solicited general symptoms were drowsiness, fever (axillary temperature above or equal (≥) 37.5°C), irritability, loss of appetite, shivering, sweating and vomiting. Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = general symptom that prevented normal activity. Grade 3 temperature = axillary temperature \> 39.0°C. Related = symptom assessed as causally related to study vaccination. This outcome presents results for subjects aged between 3 and 5 years participating in Phases A, B and C of the study. |
| Number of Subjects With Serious Adverse Events (SAEs) | During the entire study (Day 0 to Month 24) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination. |
| Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | During a 21 day follow-up period after the first vaccination, during a 30-day follow-up period after the second vaccination | An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event. Grade 3 AE = AE that prevented normal activity, everyday activities, or required intervention of a physician/healthcare provider. Related = symptom assessed as causally related to study vaccination. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within(normal), or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for ALT for subjects participating in Phase A of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for AST for subjects participating in Phase A of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for BUN for subjects participating in Phase A of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CPK for subjects participating in Phase A of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CREA for subjects participating in Phase A of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for LDH for subjects participating in Phase A of the study |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | At Days 21 and 42 and Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for ALT for subjects participating in Phase B of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for AST for subjects participating in Phase B of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for BUN for subjects participating in Phase B of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CPK for subjects participating in Phase B of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CREA for subjects participating in Phase B of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for LDH for subjects participating in Phase B of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for ALT for subjects participating in Phase C of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for AST for subjects participating in Phase C of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within(normal), or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for BUN for subjects participating in Phase C of the study. |
| Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CREA for subjects participating in Phase C of the study. |
| Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CPK for subjects participating in Phase C of the study. |
| Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | At Days 21, and 42, and at Months 6, 12 and 24 | Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for LDH for subjects participating in Phase C of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents ALT results for subjects participating in Phase A of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results for subjects participating in Phase A of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents BUN results for subjects participating in Phase A of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CREA results, for subjects participating in Phase A of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CPK results for subjects participating in Phase A of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents LDH results for subjects participating in Phase A of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results, for subjects participating to Phase B of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results, for subjects participating to Phase B of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | At Days 0, 21 and 42 and at Month 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CREA results, for subjects participating in Phase B of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents LDH results, for subjects participating to Phase B of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | At Days 0, 21, and 42, and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents BUN results, for subjects participating to Phase B of the study. |
| Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | At Days 0, 21 and 42 and at Months 6, 12 and 24 | Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents BUN results, for subjects participating to Phase C of the study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | At Days 21 and 42 | A seroconverted subject as regards to serum neutralizing antibodies against influenza disease was a subject with a minimum 4-fold increase in serum neutralizing antibody titer at post-vaccination. The flu strain assessed was A/Vietnam/1194/2004 (A/VIET). This outcome presents results for subjects participating to Phase A of the study. |
| Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | At Months 6, 12 and 24 | Titers of serum neutralizing antibodies are presented as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off value of 1:28. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO) strains. Results presented are for subjects participating in Phase A of the study. Subjects participating to Phases B and C of the study were not analysed at these persistence time points for this outcome. |
| Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | At Months 6, 12 and 24. | A seroconverted subject as regards to neutralizing antibody response was a subject with a minimum 4-fold increase in neutralizing antibody titer at post-vaccination. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO) strains. Results presented are for subjects participating in Phase A of the study. Subjects participating to Phases B and C of the study were not analysed at these persistence time points for this outcome. |
| Number of Subjects With Adverse Events of Specific Interest (AESIs) | Throughout the entire study period, from Day 0 to Month 24 | AESIs are adverse events such as clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. AESIs assessed included neuroinflammatory disorders such as cranial nerve disorders, multiple sclerosis,transverse myelitis, Guillain-Barré syndromeor neuritis), musculoskeletal disorders (such as systemic lupus erythematosus, cutaneous lupus, polymyositis, rheumatoid arthritis, reactive arthritis, psoriatic arthropathy, or undifferentiated spondyloarthropathy), gastrointestinal disorders (such as Crohn's disease, ulcerative colitis, ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, Addison's disease). skin disorders (such as psoriasis, vitiligo, Raynaud's phenomenon, or autoimmune bullous skin diseases), and other conditions as autoimmune hemolytic anemia, thrombocytopenias, antiphospholipid syndrome, vasculitis, autoimmune hepatitis, or sarcoidosis. |
| Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | At Days 0, 21 and 42 | Titers of serum neutralizing antibodies are presented as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off value of 1:28. The influenza strain assessed was A/Vietnam/1194/04 (A/VIET).Results presented are for subjects participating in Phase A of the study |
Countries
Spain
Participant flow
Recruitment details
138 subjects were enrolled as part of the first 107066/Phase A part of this NCT00502593 study. This first part was then followed by a second and third part (Phases B \[study 108498\] and C \[study 108500\] during which 134 and 133 subjects were enrolled, respectively. Duration of the study was of 24 months for all subjects.
Pre-assignment details
For safety reasons, subjects in each group were enrolled in a staggered manner, with enrolment taking place sequentially into 2 age strata, '6-9 years' 1st, and '3-5 years' next.
Participants by arm
| Arm | Count |
|---|---|
| GSK1562902A -A Lot 1 3-5Y Group Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 51 |
| Fluarix-A 3-5Y Group Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 18 |
| GSK1562902A-A Lot 1 6-9Y Group Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 51 |
| Fluarix-A 6-9Y Group Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 18 |
| GSK1562902A-B Lot 2 3-5Y Group Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 51 |
| Fluarix-B 3-5Y Group Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 17 |
| GSK1562902A-B Lot 2 6-9Y Group Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 49 |
| Fluarix-B 6-9Y Group Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 17 |
| GSK1562902A-C Lot 3 3-5Y Group Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 49 |
| Fluarix-C 3-5Y Group Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 17 |
| GSK1562902A-C Lot 3 6-9Y Group Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 49 |
| Fluarix-C 6-9Y Group Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21. | 18 |
| Total | 405 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 6 | 2 | 2 | 0 | 3 | 0 | 3 | 0 | 1 | 0 |
| Overall Study | Withdrawn unspecified reason | 1 | 1 | 3 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | GSK1562902A-B Lot 2 3-5Y Group | GSK1562902A -A Lot 1 3-5Y Group | Fluarix-A 3-5Y Group | GSK1562902A-A Lot 1 6-9Y Group | Fluarix-A 6-9Y Group | Fluarix-B 3-5Y Group | GSK1562902A-B Lot 2 6-9Y Group | Fluarix-B 6-9Y Group | GSK1562902A-C Lot 3 3-5Y Group | Fluarix-C 3-5Y Group | GSK1562902A-C Lot 3 6-9Y Group | Fluarix-C 6-9Y Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 4.2 Years STANDARD_DEVIATION 0.85 | 3.9 Years STANDARD_DEVIATION 0.84 | 3.6 Years STANDARD_DEVIATION 0.7 | 7.6 Years STANDARD_DEVIATION 1.06 | 7.6 Years STANDARD_DEVIATION 1.38 | 4.4 Years STANDARD_DEVIATION 0.79 | 7.3 Years STANDARD_DEVIATION 1.28 | 7.2 Years STANDARD_DEVIATION 1.2 | 4.2 Years STANDARD_DEVIATION 0.85 | 3.9 Years STANDARD_DEVIATION 0.93 | 7.0 Years STANDARD_DEVIATION 1.06 | 7.4 Years STANDARD_DEVIATION 0.98 | 6.1 Years STANDARD_DEVIATION 0.92 |
| Sex: Female, Male Female | 25 Participants | 25 Participants | 9 Participants | 24 Participants | 7 Participants | 10 Participants | 19 Participants | 3 Participants | 22 Participants | 11 Participants | 18 Participants | 9 Participants | 182 Participants |
| Sex: Female, Male Male | 26 Participants | 26 Participants | 9 Participants | 27 Participants | 11 Participants | 7 Participants | 30 Participants | 14 Participants | 27 Participants | 6 Participants | 31 Participants | 9 Participants | 223 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 42 / 51 | 17 / 18 | 48 / 51 | 14 / 18 | 42 / 51 | 11 / 17 | 41 / 49 | 13 / 17 | 43 / 49 | 13 / 17 | 46 / 49 | 17 / 18 |
| serious Total, serious adverse events | 0 / 51 | 0 / 18 | 0 / 51 | 0 / 18 | 1 / 51 | 1 / 17 | 0 / 49 | 0 / 17 | 2 / 49 | 0 / 17 | 1 / 49 | 0 / 18 |
Outcome results
Primary
Number of Seroconverted Subjects Against 2 Strains of Influenza Disease
A seroconverted subject was a subject with a pre-vaccination serum haemagglutination-inhibition (HI) antibody titer below (\<) 1:10 and a post-vaccination HI antibody titer above than or equal to (≥)1:40 or a pre-vaccination HI antibody titer ≥ 1:10 and at least four-fold increase in post-vaccination HI antibody titer. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Day 21
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 20 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 19 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 20 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 3 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 17 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
Primary
Number of Seroconverted Subjects Against 2 Strains of Influenza Disease
A seroconverted subject was a subject with a pre-vaccination serum haemagglutination-inhibition (HI) antibody titer \< 1:10 and a post-vaccination HI antibody titer ≥1:40 or a pre-vaccination HI antibody titer ≥ 1:10 and at least four-fold increase in post-vaccination HI antibody titer. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Month 24
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 18 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 8 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 19 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 30 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 2 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 18 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 19 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 14 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 10 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 23 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 1 Participants |
Primary
Number of Seroconverted Subjects Against 2 Strains of Influenza Disease
A seroconverted subject was a subject with a pre-vaccination serum haemagglutination-inhibition (HI) antibody titer \< 1:10 and a post-vaccination HI antibody titer ≥1:40 or a pre-vaccination HI antibody titer ≥ 1:10 and at least four-fold increase in post-vaccination HI antibody titer. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Month 12
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 18 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 8 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 16 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 17 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 7 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 20 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 12 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 13 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 22 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 15 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroconverted Subjects Against 2 Strains of Influenza Disease
A seroconverted subject was a subject with a pre-vaccination serum haemagglutination-inhibition (HI) antibody titer \< 1:10 and a post-vaccination HI antibody titer ≥1:40 or a pre-vaccination HI antibody titer ≥ 1:10 and at least four-fold increase in post-vaccination HI antibody titer. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Month 6
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 28 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 25 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 23 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 32 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 12 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 31 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 24 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 20 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 25 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 32 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroconverted Subjects Against 2 Strains of Influenza Disease
A seroconverted subject was a subject with a pre-vaccination serum haemagglutination-inhibition (HI) antibody titer \< 1:10 and a post-vaccination HI antibody titer ≥1:40 or a pre-vaccination HI antibody titer ≥ 1:10 and at least four-fold increase in post-vaccination HI antibody titer. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Day 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 35 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 32 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 32 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 41 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 31 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 44 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 44 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 42 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 34 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 43 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease
A seroprotected subject was defined as a vaccinated subject with a haemagglutination-inhibition (HI) antibody titer above or equal to the seroprotection threshold of 1:40. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO).
Time frame: At Day 21
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 13 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 20 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 19 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 20 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 3 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 17 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease
A seroprotected subject was defined as a vaccinated subject with a serum HI antibody titer ≥ 1:40, a level of HI antibody that has been viewed as correlating with protection against influenza. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO).
Time frame: At Month 24
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 18 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 9 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 30 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 19 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 2 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 18 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 14 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 19 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 23 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 10 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 1 Participants |
Primary
Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease
A seroprotected subject was defined as a vaccinated subject with a haemagglutination-inhibition (HI) antibody titer above or equal to the seroprotection threshold of 1:40. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO)
Time frame: At Month 12
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 18 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 9 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 7 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 16 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 17 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 1 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 7 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 20 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 13 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 12 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 15 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 22 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease
A seroprotected subject was defined as a vaccinated subject with a haemagglutination-inhibition (HI) antibody titer above or equal to the seroprotection threshold of 1:40. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO)
Time frame: At Month 6
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 28 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 28 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 23 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 33 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 12 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 31 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 24 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 20 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 25 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 32 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease
A seroprotected subject was defined as a vaccinated subject with a haemagglutination-inhibition (HI) antibody titer above or equal to the seroprotection threshold of 1:40. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO).
Time frame: At Day 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 35 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 32 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 32 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 41 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 31 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 44 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 44 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 42 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 34 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 43 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
Primary
Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease
A seroprotected subject was defined as a vaccinated subject with a haemagglutination-inhibition (HI) antibody titer above or equal to the seroprotection threshold of 1:40. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/5/2005 (A/INDO).
Time frame: At Day 0
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/VIET | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Seroprotected Subjects Against the 2 Strains of Influenza Disease | A/INDO | 0 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, fever (axillary temperature above or equal (≥) 37.5°C), irritability, loss of appetite, shivering, sweating and vomiting. Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = general symptom that prevented normal activity. Grade 3 temperature = axillary temperature \> 39.0°C. Related = symptom assessed as causally related to study vaccination. This outcome presents results for subjects aged between 3 and 5 years participating in Phases A, B and C of the study.
Time frame: During the 7-day (Days 0-6) follow-up period after any vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 irritability | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related irritability | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any drowsiness | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39degC (Axillary) | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any irritability | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever (Axillary) | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 loss of appetite | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 drowsiness | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related vomiting | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related loss of appetite | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related shivering | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 shivering | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any loss of appetite | 12 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 vomiting | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any vomiting | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever (Axillary) >=37.5 deg C | 8 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related drowsiness | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any drowsiness | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related loss of appetite | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 shivering | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related vomiting | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever (Axillary) >=37.5 deg C | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any vomiting | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39degC (Axillary) | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever (Axillary) | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any irritability | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 irritability | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related drowsiness | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related irritability | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 vomiting | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 drowsiness | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any loss of appetite | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related shivering | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 loss of appetite | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever (Axillary) >=37.5 deg C | 10 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 irritability | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related vomiting | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any loss of appetite | 8 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 shivering | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 vomiting | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related irritability | 9 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 loss of appetite | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related shivering | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever (Axillary) | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related drowsiness | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 drowsiness | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related loss of appetite | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any irritability | 13 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any drowsiness | 9 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39degC (Axillary) | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any vomiting | 6 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any irritability | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any vomiting | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 vomiting | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related vomiting | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever (Axillary) >=37.5 deg C | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any drowsiness | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39degC (Axillary) | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever (Axillary) | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 irritability | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related irritability | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any loss of appetite | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 loss of appetite | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 drowsiness | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related loss of appetite | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 shivering | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related shivering | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related drowsiness | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 loss of appetite | 5 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any loss of appetite | 15 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related irritability | 15 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 3 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related shivering | 9 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 irritability | 1 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any irritability | 18 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever (Axillary) | 17 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any drowsiness | 12 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any vomiting | 6 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 4 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39degC (Axillary) | 5 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever (Axillary) >=37.5 deg C | 18 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related vomiting | 3 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 vomiting | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related drowsiness | 12 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 10 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 drowsiness | 2 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 1 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 shivering | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related loss of appetite | 13 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related vomiting | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any drowsiness | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 drowsiness | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related drowsiness | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever (Axillary) >=37.5 deg C | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39degC (Axillary) | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any irritability | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 irritability | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related irritability | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any loss of appetite | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 loss of appetite | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related loss of appetite | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 shivering | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related shivering | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any vomiting | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 vomiting | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever (Axillary) | 0 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Solicited general symptoms were arthralgia, fatigue, headache, muscle aches, shivering and fever, assessed as oral temperature above or equal (≥) 37.0 degrees Celsius (°C). Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = general symptom that prevented normal activity, everyday activities, or required intervention of a physician/healthcare provider. Grade 3 fever= oral temperature ≥ 39.0°C. Related = symptom assessed as causally related to study vaccination. This outcome presents results related to subjects aged 6 to 9 years participating in the study phases A, B and C.
Time frame: During the 7-day (Days 0-6) follow-up period after any vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related arthralgia | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related gastrointestinal symptoms | 8 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any gastrointestinal symptoms | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 gastrointestinal symptoms | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any fatigue | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related myalgia | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 myalgia | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any arthralgia | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 fatigue | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any myalgia | 10 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fatigue | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related headache | 16 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 arthralgia | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >=37.5 deg C | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 headache | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39.0 deg C | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any headache | 20 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >=37.5 deg C | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 fatigue | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related gastrointestinal symptoms | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any myalgia | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 headache | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any gastrointestinal symptoms | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any arthralgia | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 gastrointestinal symptoms | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any fatigue | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fatigue | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 arthralgia | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related myalgia | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related headache | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related arthralgia | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 myalgia | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39.0 deg C | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any headache | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any fatigue | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 fatigue | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fatigue | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >=37.5 deg C | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39.0 deg C | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 arthralgia | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any gastrointestinal symptoms | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 gastrointestinal symptoms | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any arthralgia | 7 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related gastrointestinal symptoms | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any headache | 11 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 headache | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related arthralgia | 7 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related headache | 8 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any myalgia | 11 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 myalgia | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related myalgia | 11 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 7 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any headache | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 myalgia | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fatigue | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any arthralgia | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any fatigue | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related headache | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related myalgia | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >=37.5 deg C | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related arthralgia | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any gastrointestinal symptoms | 5 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 fatigue | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 gastrointestinal symptoms | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 headache | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any myalgia | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 arthralgia | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39.0 deg C | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related gastrointestinal symptoms | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related gastrointestinal symptoms | 13 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39.0 deg C | 7 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any headache | 25 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >=37.5 deg C | 18 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 13 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 headache | 3 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fatigue | 11 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related headache | 22 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 fatigue | 1 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering | 13 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any myalgia | 13 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related arthralgia | 7 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 6 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 myalgia | 1 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any arthralgia | 9 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related myalgia | 11 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 arthralgia | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any gastrointestinal symptoms | 16 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any fatigue | 11 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 gastrointestinal symptoms | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 6 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever | 17 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related sweating | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any arthralgia | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 arthralgia | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related arthralgia | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any fatigue | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 fatigue | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fatigue | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >=37.5 deg C | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fever >39.0 deg C | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related fever | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any gastrointestinal symptoms | 5 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 gastrointestinal symptoms | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related gastrointestinal symptoms | 3 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any headache | 3 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 headache | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related headache | 3 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any myalgia | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 myalgia | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related myalgia | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any shivering | 3 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering | 2 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any sweating | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 sweating | 0 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms
Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal activities. Grade 3 ecchymosis/induration/redness/swelling = ecchymosis/induration/redness/swelling larger than (\>) 100 millimeters (mm). All solicited local symptoms were considered to be related to study vaccination. This outcome presents results from subjects participating in Phase A of the study.
Time frame: During the 7 day follow-up period after each vaccination
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 31 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 10 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 10 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 7 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 12 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 14 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 12 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 12 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 5 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 6 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 7 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms
Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal activities. Grade 3 ecchymosis/induration/redness/swelling = ecchymosis/induration/redness/swelling larger than (\>) 100 millimeters (mm). All solicited local symptoms were considered to be related to study vaccination. This outcome presents results from subjects participating in Phase C of the study.
Time frame: During the 7-day follow-up period after each vaccination
Population: The analysis was based on theTotal Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosys >50mm | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 14 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 16 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 18 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 7 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosys >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 14 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosys >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 10 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosys >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 3 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms
Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal activities. Grade 3 ecchymosis/induration/redness/swelling = ecchymosis/induration/redness/swelling larger than (\>) 100 millimeters (mm). All solicited local symptoms were considered to be related to study vaccination. This outcome presents results from subjects participating to Phase B of the study.
Time frame: During the 7-day follow-up period after each vaccination
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 27 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 10 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 6 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any pain | 9 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Redness >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Grade 3 pain | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Swelling >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any redness | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Ecchymosis >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any induration | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Induration >50mm | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any ecchymosis | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms | Any swelling | 2 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event. Grade 3 AE = AE that prevented normal activity, everyday activities, or required intervention of a physician/healthcare provider. Related = symptom assessed as causally related to study vaccination.
Time frame: During a 21 day follow-up period after the first vaccination, during a 30-day follow-up period after the second vaccination
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 29 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 12 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 10 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 5 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 28 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 3 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 3 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 9 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 0 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 19 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 4 Participants |
| Fluarix-B 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 1 Participants |
| Fluarix-B 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 1 Participants |
| Fluarix-B 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 6 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 3 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 26 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 9 Participants |
| Fluarix-C 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 0 Participants |
| Fluarix-C 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 8 Participants |
| Fluarix-C 3-5Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 27 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 3 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 1 Participants |
| Fluarix-C 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any related AE(s) | 1 Participants |
| Fluarix-C 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any AE(s) | 6 Participants |
| Fluarix-C 6-9Y Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events | Subjects with any Grade 3 AE(s) | 1 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A
Changes from baseline are categorised as below, within(normal), or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for ALT for subjects participating in Phase A of the study.
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Unknown | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 21,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal,Day 42,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase A | ALT,Normal, Month 12,Normal | 16 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for ALT for subjects participating in Phase B of the study.
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Normal,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase B | ALT,Unknown, Month 24,Unknown | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for ALT for subjects participating in Phase C of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Normal | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Unknown | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Unknown, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 12, Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal , Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Normal, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Alanine Aminotransferase (ALT) for Subjects in Study Phase C | ALT, Above, Month 12, Below | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for AST for subjects participating in Phase A of the study.
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 6,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Unknown | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Above, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase A | AST,Unknown, Month 24,Unknown | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for AST for subjects participating in Phase B of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 6,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 6,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 12,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase B | AST,Normal,Day 42,Above | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for AST for subjects participating in Phase C of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Normal | 34 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Normal | 34 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Unknown | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 6, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Above, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Aspartate Aminotransferase (AST) in Study Phase C | AST, Normal, Month 6, Above | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CREA for subjects participating in Phase A of the study.
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Normal | 17 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 42, Unknown | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Normal, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase A | CREA, Unknown, Day 42, Normal | 1 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CREA for subjects participating in Phase B of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Normal | 49 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Unknow | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Unknow | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Unknow | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above,Day 21,Unknow | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase B | CREA,Above, Month 12,Above | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CREA for subjects participating in Phase C of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Normal | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Normal | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Normal | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Unknown | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Day 21,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Creatinine (CREA) in Study Phase C | CREA,Normal,Month 6,Normal | 17 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for BUN for subjects participating in Phase A of the study.
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42,Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Unknkwn | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above,Month 6,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Below | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Unknkwn | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Below | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42,Above | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Unknkwn | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Normal | 11 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Unknown | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Above, Day 42, Unknkwn | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Normal | 12 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase A | BUN,Normal, Month 6,Below | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for BUN for subjects participating in Phase B of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 6,Normal | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Normal | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 12,Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 12,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Normal | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 6,Normal | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 12,Normal | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 12,Normal | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Normal | 12 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Normal | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Normal | 11 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Normal | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Normal | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Normal | 11 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above,Month 6,Normal | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase B | BUN,Above, Month 12,Below | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C
Changes from baseline are categorised as below, within(normal), or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for BUN for subjects participating in Phase C of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Normal | 34 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Below | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Normal | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Normal | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Normal | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Below | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Below | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Normal | 35 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Normal | 41 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month12,Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Below,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Unknown,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Blood Urea Nitrogen (BUN) in Study Phase C | BUN,Above,Day 42,Above | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CPK for subjects participating in Phase A of the study.
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Unknown | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Normal | 12 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK, Above, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Normal, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase A | CPK,Above, Month 12,Below | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CPK for subjects participating in Phase B of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Creatine Phosphokinase (CPK) in Study Phase B | CPK,Above, Month 12,Below | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for LDH for subjects participating in Phase A of the study
Time frame: At Days 21 and 42 and Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Above | 8 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above,Month 6,Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Normal | 33 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Normal | 32 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Normal | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Unknow | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Normal | 31 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Normal | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Above | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Unknow | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above,Month 6,Normal | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Above | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Normal | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Normal | 8 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Normal | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Normal | 8 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Normal | 8 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Normal | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Normal | 7 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Unknown | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Unknow | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above,Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Unknow | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Unknown | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Unknown, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Normal | 11 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Above, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above,Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Normal, Month 6,Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Normal, Day 21, Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase A | LDH,Above, Month 12,Below | 0 Participants |
Primary
Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for LDH for subjects participating in Phase B of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 6,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Above | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Normal | 32 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Normal | 33 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Above | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Normal | 33 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Unknown | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Normal | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 12,Normal | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 6,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Above | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 12,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Normal | 34 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 6,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 12,Normal | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Normal | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Unknown, Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 24,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal, Month 6,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status as Regards to the Biochemical Parameter Lactate Dehydrogenase (LDH) in Study Phase B | LDH,Above, Month 12,Below | 0 Participants |
Primary
Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for CPK for subjects participating in Phase C of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Normal | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Normal | 34 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Unknown | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Normal | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Normal | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Normal | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Normal | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 12,Unknown | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 12,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Unknown,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 24,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Month 6,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Above,Month 6,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK,Normal,Day 42,Unknown | 0 Participants |
Primary
Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C
Changes from baseline are categorised as below, within, or above the normal ranges at each scheduled post-vaccination time point versus the category of the laboratory values at baseline. Assessed parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) Per parameter and range, it was assessed according to baseline values whether laboratory values of the subjects were below normal, normal or above the normal range. This outcome presents results for LDH for subjects participating in Phase C of the study.
Time frame: At Days 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Normal | 28 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Unknwon | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Normal | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Unknown | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Normal | 26 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Normal | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Above | 8 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Normal | 29 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Unknown | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Normal | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Normal | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Normal | 31 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Normal | 24 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Normal | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Unknown | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Normal | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Unknwon | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown, Month 6, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Normal | 7 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Normal | 8 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Above | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Unknown | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Unknown | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Normal | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Normal | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Unknown | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Unknown | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Normal | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Normal | 37 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Unknown | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Normal | 34 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Above | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Unknwon | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Normal | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Unknown | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Normal | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Unknown, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Normal | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Unknwon | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Normal,Day 21,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Normal, Month 24, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Unknown | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Unknown, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH,Above,Day 42,Normal | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Changed Status With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Above, Month 12, Unknown | 0 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results, for subjects participating to Phase B of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Aspartate Aminotransferase (AST) in Study Phase B | AST, Day 0, Normal | 16 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents BUN results for subjects participating in Phase A of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Normal | 50 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Normal | 18 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Below | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Below | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Normal | 52 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Above | 6 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 6, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 0, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 21, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Day 42, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase A | BUN, Month 24, Normal | 12 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents BUN results, for subjects participating to Phase B of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Normal | 47 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Above | 4 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 0, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 21, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Day 42, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase B | BUN, Month 24, Normal | 16 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents BUN results, for subjects participating to Phase C of the study.
Time frame: At Days 0, 21 and 42 and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Below | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Normal | 42 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Below | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Below | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Above | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Below | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Below | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Day 42, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Blood Urea Nitrogen (BUN) in Study Phase C | BUN, Month 24, Normal | 17 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CPK results for subjects participating in Phase A of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Normal | 51 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Normal | 51 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Normal | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 12, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 6, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Normal | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase A | CPK, Day 42, Above | 1 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CPK results, for subjects participating to Phase B of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Normal | 49 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Normal | 15 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase B | CPK, Month 6, Above | 2 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CPK results, for subjects participating to Phase C of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Normal | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Normal | 15 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 21, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 24, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatine Phosphokinase (CPK) in Study Phase C | CPK, Month 6, Below | 0 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CREA results, for subjects participating in Phase A of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Normal | 49 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Normal | 49 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Normal | 52 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Normal | 18 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Normal | 53 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Day 42, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase A | CREA, Month 24, Normal | 14 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CREA results, for subjects participating in Phase B of the study.
Time frame: At Days 0, 21 and 42 and at Month 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Normal | 51 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Normal | 47 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Normal | 47 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 24, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase B | CREA, Month 12, Below | 0 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents CREA results, for subjects participating to Phase C of the study.
Time frame: At Days 0, 21 and 42 and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Normal | 45 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 21, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Creatinine (CREA) in Study Phase C | CREA, Day 0, Normal | 17 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents LDH results for subjects participating in Phase A of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Normal | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Above | 11 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Above | 12 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Above | 11 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Normal | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Normal | 41 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Normal | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Above | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Above | 4 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Above | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Above | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Normal | 52 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 12, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 24, Normal | 12 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Month 6, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase A | LDH, Day 42, Above | 1 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents LDH results, for subjects participating to Phase B of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Above | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Above | 5 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Above | 9 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Above | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Above | 7 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Above | 7 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Above | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Above | 6 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 0, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 24, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase B | LDH, Day 42, Above | 3 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents LDH results, for subjects participating to Phase C of the study.
Time frame: At Days 0, 21 and 42 and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Normal | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Above | 11 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Above | 8 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Normal | 28 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Above | 7 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Normal | 32 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Above | 13 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Above | 11 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Normal | 35 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Normal | 30 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Above | 8 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Above | 5 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Above | 8 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Normal | 11 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Normal | 8 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Above | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Normal | 10 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Normal | 36 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Above | 9 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Normal | 39 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Above | 4 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Above | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Normal | 15 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 12, Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 42, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Month 24, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Regards to Lactate Dehydrogenase (LDH) in Study Phase C | LDH, Day 0, Normal | 17 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents ALT results for subjects participating in Phase A of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Normal | 47 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Normal | 48 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Normal | 50 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Normal | 49 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Normal | 18 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Normal | 51 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Normal | 41 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 24, Normal | 14 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase A | ALT, Month 6, Below | 0 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results, for subjects participating to Phase B of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Normal | 50 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Normal | 44 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Normal | 48 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 0, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 24, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase B | ALT, Day 42, Above | 1 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents ALT results, for subjects participating to Phase C of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Normal | 39 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Day 0,Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Normal | 42 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Day 0,Normal | 15 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Day 0,Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Normal | 46 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Above | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 21,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 0,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Day 0,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALT) in Study Phase C | ALT,Day 42,Above | 0 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results for subjects participating in Phase A of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Above | 4 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Above | 6 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Normal | 43 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Normal | 46 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Normal | 42 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Normal | 46 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Normal | 18 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Normal | 13 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Above | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Normal | 16 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Normal | 44 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Above | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Normal | 51 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 0, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 21, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 12, Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Day 42, Normal | 16 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase A | AST, Month 24, Normal | 14 Participants |
Primary
Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C
Assessed biochemical parameters were alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). Per parameter , it was assessed whether subjects had laboratory values below normal, normal, or above normal range. This outcome presents AST results, for subjects participating to Phase C of the study.
Time frame: At Days 0, 21, and 42, and at Months 6, 12 and 24
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Above | 2 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Above | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Normal | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Above | 3 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Normal | 44 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Normal | 38 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Above | 1 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Normal | 39 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Day 21,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Normal | 12 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Above | 2 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Normal | 14 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 6,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Above | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Above | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Normal | 17 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Below | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Normal | 12 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Day 21,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Above | 5 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Above | 1 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Normal | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Above | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Above | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 6,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Normal | 43 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Normal | 40 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Below | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Normal | 45 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Above | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Normal | 17 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 0,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 12,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 24,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Month 6,Below | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 21,Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST,Day 42,Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Normal | 18 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Month 6, Above | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Aspartate Aminotransferase (AST) in Study Phase C | AST, Day 21,Below | 0 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination.
Time frame: During the entire study (Day 0 to Month 24)
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
| Fluarix-C 3-5Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| Fluarix-C 6-9Y Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Day 21
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.7 Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 2.4 Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 4.4 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.1 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.1 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 4.7 Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.0 Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.5 Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.1 Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.5 Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.2 Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Day 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 78.5 Fold |
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 10.7 Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 108.1 Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 12.2 Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 14.7 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 132.3 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 13.0 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 123.2 Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 191.3 Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 33.6 Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 18.5 Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 176.7 Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO).
Time frame: At Month 6
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.9 Fold |
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.4 Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.2 Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 6.1 Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.2 Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.2 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 4.3 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 9.1 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.1 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 2.4 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 8.6 Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 16.0 Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 8.5 Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 7.4 Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 12.3 Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (A/VIET) and A/Indonesia/5/2005 (A/INDO).
Time frame: At Month 12
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 2.8 Fold |
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 2.6 Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.9 Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 2.2 Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.2 Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.1 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 3.3 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 4.0 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.0 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.2 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 3.0 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 4.5 Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.3 Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.0 Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 3.7 Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 4.8 Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.5 Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 4.1 Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.1 Fold |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (A/VIET) and A/Indonesia/5/2005 (A/INDO).
Time frame: At Month 24
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 3.0 Fold |
| GSK1562902A-A Lot 1 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 2.0 Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-A 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 2.5 Fold |
| GSK1562902A-A Lot 1 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.5 Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-A 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 4.5 Fold |
| GSK1562902A-B Lot 2 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 10.4 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.4 Fold |
| Fluarix-B 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.1 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 1.7 Fold |
| GSK1562902A-B Lot 2 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 4.0 Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Fold |
| Fluarix-B 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 11.2 Fold |
| GSK1562902A-C Lot 3 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.5 Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.3 Fold |
| Fluarix-C 3-5Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 3.6 Fold |
| GSK1562902A-C Lot 3 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 7.3 Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Fold |
| Fluarix-C 6-9Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 1.2 Fold |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Titers of serum HI antibodies are presented as geometric mean titers (GMTs). The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10
Time frame: At Month 24
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 14.9 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 10.1 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 13.2 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 7.7 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 22.7 Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 52.2 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 6.8 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.3 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 8.7 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 20.1 Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 55.8 Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 27.5 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 6.6 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 18.2 Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 36.5 Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 6.2 Titer |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Titers of serum HI antibodies are presented as geometric mean titers (GMTs). The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10
Time frame: At Day 21
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 8.7 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.2 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.2 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 12.1 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.5 Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 22.7 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.3 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 23.7 Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 7.7 Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 25.0 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.7 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 27.3 Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 6.0 Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Titers are presented as geometric mean titers (GMTs). The 2 flu strains assessed were A/Vietnam/1194/2004 (A/VIET) and A/Indonesia/5/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10
Time frame: At Day 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 392.7 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 53.5 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 540.3 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 60.8 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 73.7 Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 678.1 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 64.9 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 615.8 Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 956.4 Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 167.9 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 92.5 Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 883.5 Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Titers of serum HI antibodies are presented as geometric mean titers (GMTs). The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10.
Time frame: At Month 6
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 29.3 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 6.9 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.9 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 33.4 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 6.6 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 21.7 Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 46.3 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 11.9 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 43.2 Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 80.0 Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 42.5 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 36.8 Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 61.5 Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Titers are presented as geometric mean titers (GMTs). The 2 flu strains assessed were A/Vietnam/1194/2004 (A/VIET) and A/Indonesia/5/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10
Time frame: At Month 12
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 13.9 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 13.0 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 12.0 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 10.5 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.8 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.5 Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 16.4 Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 19.8 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.2 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 5.9 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 22.4 Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 15.0 Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.2 Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 6.5 Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 23.9 Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 18.5 Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 27.7 Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | 20.4 Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.4 Titer |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Titers of serum HI antibodies are presented as geometric mean titers (GMTs). The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO). The cut-off of the assay was the seropositivity cut-off value of 1:10.
Time frame: At Day 0
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | 5.1 Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-B Lot 2 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-B 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| Fluarix-C 3-5Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
| GSK1562902A-C Lot 3 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/INDO | NA Titer |
| Fluarix-C 6-9Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/VIET | NA Titer |
Secondary
Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response
A seroconverted subject as regards to neutralizing antibody response was a subject with a minimum 4-fold increase in neutralizing antibody titer at post-vaccination. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO) strains. Results presented are for subjects participating in Phase A of the study. Subjects participating to Phases B and C of the study were not analysed at these persistence time points for this outcome.
Time frame: At Months 6, 12 and 24.
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 12 | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 6 | 41 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 24 | 40 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 24 | 36 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 12 | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 6 | 34 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 12 | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 6 | 0 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 24 | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 12 | 3 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 6 | 9 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 24 | 3 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 24 | 23 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 6 | 38 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 12 | 23 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 6 | 31 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 12 | 31 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 24 | 33 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 24 | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 12 | 2 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 12 | 3 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 6 | 13 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/INDO, Month 6 | 1 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against 2 Strains of Influenza Disease as Regards to Neutralizing Antibody Response | A/VIET, Month 24 | 4 Participants |
Secondary
Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies
A seroconverted subject as regards to serum neutralizing antibodies against influenza disease was a subject with a minimum 4-fold increase in serum neutralizing antibody titer at post-vaccination. The flu strain assessed was A/Vietnam/1194/2004 (A/VIET). This outcome presents results for subjects participating to Phase B of the study.
Time frame: At Days 21 and 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 25 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 40 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 2 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 35 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 42 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 11 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 11 Participants |
Secondary
Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies
A seroconverted subject as regards to serum neutralizing antibodies against influenza disease was a subject with a minimum 4-fold increase in serum neutralizing antibody titer at post-vaccination. The flu strain assessed was A/Vietnam/1194/2004 (A/VIET). This outcome presents results for subjects participating to Phase C of the study.
Time frame: At Days 21 and 42
Population: The analysis was based on the According to protocol (ATP) cohort for immunogenicity, which included all subjects meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria and no major deviation from protocol, for whom immunogenicity data for at least one antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 37 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 29 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 7 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 23 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 42 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 5 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 3 Participants |
Secondary
Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies
A seroconverted subject as regards to serum neutralizing antibodies against influenza disease was a subject with a minimum 4-fold increase in serum neutralizing antibody titer at post-vaccination. The flu strain assessed was A/Vietnam/1194/2004 (A/VIET). This outcome presents results for subjects participating to Phase A of the study.
Time frame: At Days 21 and 42
Population: The analysis was based on the According to protocol (ATP) cohort for immunogenicity, which included all subjects meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria and no major deviation from protocol, for whom immunogenicity data for at least one antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 31 Participants |
| GSK1562902A-A Lot 1 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 43 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 6 Participants |
| Fluarix-A 3-5Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 8 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 42 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 28 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 42 | 10 Participants |
| Fluarix-A 6-9Y Group | Number of Seroconverted Subjects Against One Strain of Influenza Disease With Respect to Serum Neutralizing Antibodies | A/VIET, Day 21 | 10 Participants |
Secondary
Number of Subjects With Adverse Events of Specific Interest (AESIs)
AESIs are adverse events such as clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. AESIs assessed included neuroinflammatory disorders such as cranial nerve disorders, multiple sclerosis,transverse myelitis, Guillain-Barré syndromeor neuritis), musculoskeletal disorders (such as systemic lupus erythematosus, cutaneous lupus, polymyositis, rheumatoid arthritis, reactive arthritis, psoriatic arthropathy, or undifferentiated spondyloarthropathy), gastrointestinal disorders (such as Crohn's disease, ulcerative colitis, ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, Addison's disease). skin disorders (such as psoriasis, vitiligo, Raynaud's phenomenon, or autoimmune bullous skin diseases), and other conditions as autoimmune hemolytic anemia, thrombocytopenias, antiphospholipid syndrome, vasculitis, autoimmune hepatitis, or sarcoidosis.
Time frame: Throughout the entire study period, from Day 0 to Month 24
Population: The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom safety data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 1 Participants |
| Fluarix-A 3-5Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
| GSK1562902A-A Lot 1 6-9Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
| Fluarix-A 6-9Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 1 Participants |
| GSK1562902A-B Lot 2 3-5Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 1 Participants |
| Fluarix-B 3-5Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 1 Participants |
| GSK1562902A-B Lot 2 6-9Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
| Fluarix-B 6-9Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
| GSK1562902A-C Lot 3 3-5Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 1 Participants |
| Fluarix-C 3-5Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
| GSK1562902A-C Lot 3 6-9Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
| Fluarix-C 6-9Y Group | Number of Subjects With Adverse Events of Specific Interest (AESIs) | 0 Participants |
Secondary
Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease
Titers of serum neutralizing antibodies are presented as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off value of 1:28. The influenza strain assessed was A/Vietnam/1194/04 (A/VIET). Results presented are for subjects participating in Phase C of the study.
Time frame: At Days 0, 21 and 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 4578.3 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 37.3 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 473.8 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 111.3 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 35.5 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 102.3 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 313.5 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 25.6 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 3032.5 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 27.1 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 77.6 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 190.1 Titer |
Secondary
Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease
Titers of serum neutralizing antibodies are presented as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off value of 1:28. The influenza strain assessed was A/Vietnam/1194/04 (A/VIET). Results presented are for subjects participating in Phase B of the study.
Time frame: At Days 0, 21 and 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 1553.2 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 65.5 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 344.7 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 124.9 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 48.8 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 86.9 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 461.7 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 46.2 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 1519.4 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 25.6 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 154.6 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 148.3 Titer |
Secondary
Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease
Titers of serum neutralizing antibodies are presented as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off value of 1:28. The influenza strain assessed was A/Vietnam/1194/04 (A/VIET).Results presented are for subjects participating in Phase A of the study
Time frame: At Days 0, 21 and 42
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, e.g. for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 31.0 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 173.5 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 1044.4 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 29.0 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 98.2 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 158.4 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 32.2 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 177.5 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 1155.1 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 0 | 18.2 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 42 | 104.5 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 1 Strain of Influenza Disease | A/VIET, Day 21 | 97.2 Titer |
Secondary
Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease
Titers of serum neutralizing antibodies are presented as geometric mean titers (GMTs). The cut-off of the assay was the seropositivity cut-off value of 1:28. The 2 influenza strains assessed were A/Vietnam/1194/04 (A/VIET) and A/Indonesia/05/2005 (A/INDO) strains. Results presented are for subjects participating in Phase A of the study. Subjects participating to Phases B and C of the study were not analysed at these persistence time points for this outcome.
Time frame: At Months 6, 12 and 24
Population: The analysis was performed on the According-to-Protocol cohort for persistence, which included all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component on Month 6/Day 180, Month 12 and Month 24.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 6 | 781.2 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 12 | 238.9 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 24 | 302.5 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 6 | 113.8 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 12 | 170.8 Titer |
| GSK1562902A-A Lot 1 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 24 | 188.5 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 24 | 31.8 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 6 | 17.0 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 6 | 208.5 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 24 | 39.4 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 12 | 35.4 Titer |
| Fluarix-A 3-5Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 12 | 18.2 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 12 | 179.4 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 24 | 234.5 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 6 | 106.8 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 24 | 146.0 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 12 | 139.7 Titer |
| GSK1562902A-A Lot 1 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 6 | 756.1 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 12 | 21.9 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 24 | 20.5 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 12 | 27.6 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/INDO, Month 6 | 16.9 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 6 | 482.3 Titer |
| Fluarix-A 6-9Y Group | Titers for Serum Neutralizing Antibodies Against 2 Strains of Influenza Disease | A/VIET, Month 24 | 46.6 Titer |